Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 123-129

  Abujrad, H ^a   Mayne, J ^b   Ruzicka, M ^a,d   Cousins, M ^a   Raymond, A ^a   Cheesman, J ^a   Taljaard, M ^c,d   Sorisky, A ^a,d   Burns, K ^a,d   Ooi, T C ^a,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Chronic kidney disease; Hemodialysis; LDL C; PCSK9; Statin

Indexed keywords

CHRONIC KIDNEY DISEASE; HEMODIALYSIS; LDL-C; PCSK9; STATIN;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERINE ENDOPEPTIDASES;

EID: 84893863331     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.030     Document Type: Article

References (35)

1. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006, 290(2):F262-F272. [Epub 2006/01/13].
2. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA: J Am Med Assoc 2004, 291(4):451-459. [Epub 2004/01/30].
3. Longenecker J.C., Coresh J., Powe N.R., et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. JAm Soc Nephrol JASN 2002, 13(7):1918-1927. [Epub 2002/06/29].
4. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003, 100(3):928-933. [Epub 2003/01/29].
5. Zaid A., Roubtsova A., Essalmani R., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48(2):646-654. [Epub 2008/07/31].
6. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003, 34(2):154-156. [Epub 2003/05/06].
7. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. JBiol. Chem 2004, 279(48):50630-50638. [Epub 2004/09/24].
8. Mayne J., Raymond A., Chaplin A., et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007, 361(2):451-456. [Epub 2007/07/25].
9. Zhang D.W., Lagace T.A., Garuti R., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. JBiol Chem 2007, 282(25):18602-18612. [Epub 2007/04/25].
10. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 2005, 102(6):2069-2074. [Epub 2005/01/29].
11. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. NEngl J Med 2012, 366(12):1108-1118. [Epub 2012/03/23].
12. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA: J Am Med Assoc 2012, 308(23):2497-2506. [Epub 2012/11/07].
13. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380(9858):1995-2006. [Epub 2012/11/13].
14. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380(9858):2007-2017. [Epub 2012/11/13].
15. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126(20):2408-2417. [Epub 2012/11/07].
16. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380(9836):29-36. [Epub 2012/05/29].
17. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. JAm Coll Cardiol 2012, 59(25):2344-2353. [Epub 2012/04/03].
18. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37(2):161-165. [Epub 2005/01/18].
19. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54(6):1038-1045. [Epub 2008/04/26].
20. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. JClin Endocrinol Metabol 2009, 94(7):2537-2543. [Epub 2009/04/09].
21. Mayne J., Dewpura T., Raymond A., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Disease 2008, 7:22. [Epub 2008/06/13].
22. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. JLipid Res 2008, 49(2):394-398. [Epub 2007/11/24].
23. Dubuc G., Tremblay M., Pare G., et al. Anew method for measurement of total plasma PCSK9: clinical applications. JLipid Res 2010, 51(1):140-149. [Epub 2009/07/03].
24. Kronenberg F., Trenkwalder E., Kronenberg M.F., Konig P., Utermann G., Dieplinger H. Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney Int 1998, 54(4):1385-1389. [Epub 1998/10/10].
25. Martino F., Lorenzen J., Schmidt J., et al. Circulating microRNAs are not eliminated by hemodialysis. PloS One 2012, 7(6):e38269. [Epub 2012/06/21].
26. Young P., Lombi F., Finn B.C., et al. "Sindrome complejo de malnutricion e inflamacion" en la hemodialisis cronica. Medicina 2011, 71(1):66-72. [Epub 2011/02/08].
27. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. JLipid Research 2010, 51(9):2714-2721. [Epub 2010/06/08].
28. Mayne J., Ooi T.C., Raymond A., et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Disease 2013, 12:70. [Epub 2013/05/15].
29. Persson L., Cao G., Stahle L., et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vascul Biol 2010, 30(12):2666-2672. [Epub 2010/10/05].
30. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. JLipid Res 2010, 51(11):3359-3363. [Epub 2010/08/19].
31. Verges B., Duvillard L., Brindisi M.C., et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis 2011, 219(1):342-348. [Epub 2011/09/06].
32. Brouwers M.C., Troutt J.S., van Greevenbroek M.M., et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis 2011, 217(1):263-267. [Epub 2011/04/19].
33. Kwakernaak A.J., Lambert G., Slagman M.C., et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis 2013, 226(2):459-465. [Epub 2012/12/25].
34. Le May C., Kourimate S., Langhi C., et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009, 29(5):684-690. [Epub 2009/03/07].
35. Roubtsova A., Munkonda M.N., Awan Z., et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011, 31(4):785-791. [Epub 2011/01/29].